Allarity Therapeutics Valuation
| ALLR Stock | USD 1.10 0.01 0.90% |
Today, the firm appears to be undervalued. Allarity Therapeutics shows a prevailing Real Value of $2.06 per share. The current price of the firm is $1.1. Our model approximates the value of Allarity Therapeutics from analyzing the firm fundamentals such as Return On Equity of -1.22, current valuation of (12.25 M), and Shares Owned By Insiders of 12.30 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Allarity Therapeutics' valuation include:
Price Book 0.3762 | Enterprise Value -12.2 M | Enterprise Value Ebitda (0.08) |
Undervalued
Today
Please note that Allarity Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of Allarity Therapeutics is based on 3 months time horizon. Increasing Allarity Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Allarity stock is determined by what a typical buyer is willing to pay for full or partial control of Allarity Therapeutics. Since Allarity Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Allarity Stock. However, Allarity Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.1 | Real 2.06 | Target 5.0 | Hype 1.24 | Naive 1.01 |
The intrinsic value of Allarity Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Allarity Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Allarity Therapeutics helps investors to forecast how Allarity stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Allarity Therapeutics more accurately as focusing exclusively on Allarity Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Allarity Therapeutics' intrinsic value based on its ongoing forecasts of Allarity Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Allarity Therapeutics' closest peers.
Allarity Therapeutics Cash |
|
Allarity Valuation Trend
Allarity Therapeutics' real value is important for investors to make better decisions and a more accurate overall view of Allarity Therapeutics' financial worth over time. Using both Allarity Therapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Allarity Therapeutics Total Value Analysis
Allarity Therapeutics is presently expected to have valuation of (12.25 M) with market capitalization of 2.06 M, debt of 1.3 M, and cash on hands of 7.73 M. The negative valuation of Allarity Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Allarity Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(12.25 M) | 2.06 M | 1.3 M | 7.73 M |
Allarity Therapeutics Asset Utilization
One of the ways to look at asset utilization of Allarity is to check how much profit was generated for every dollar of assets it reports. Allarity Therapeutics shows a negative utilization of assets of -0.48 percent, losing $0.004772 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Allarity Therapeutics shows how discouraging it operates for each dollar spent on its assets.Allarity Therapeutics Ownership Allocation
Allarity Therapeutics shows 12.3 percent of its outstanding shares held by insiders and 1.2 percent owned by other corporate entities.Allarity Therapeutics Profitability Analysis
Net Loss for the year was (11.9 M) with loss before overhead, payroll, taxes, and interest of (36.35 M).About Allarity Therapeutics Valuation
The stock valuation mechanism determines Allarity Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Allarity Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Allarity Therapeutics. We calculate exposure to Allarity Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Allarity Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -37 K | -38.9 K | |
| Pretax Profit Margin | (142.33) | (149.44) | |
| Operating Profit Margin | (132.08) | (138.69) |
Allarity Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Allarity Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 2 B |
Allarity Therapeutics Current Valuation Indicators
Allarity Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Allarity Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Allarity Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Allarity Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Allarity Therapeutics' worth.Additional Tools for Allarity Stock Analysis
When running Allarity Therapeutics' price analysis, check to measure Allarity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allarity Therapeutics is operating at the current time. Most of Allarity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Allarity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allarity Therapeutics' price. Additionally, you may evaluate how the addition of Allarity Therapeutics to your portfolios can decrease your overall portfolio volatility.